The Legal 500 > Wikborg Rein > Oslo, NORWAY > Press Releases

Wikborg Rein

Wikborg Rein Overview PDF

KRONPRINSESSE MÄRTHAS PLASS 1, PO BOX 1513 VIKA, 0117 OSLO, NORWAY

Tel:: Work +47 22 82 75 00
Fax:: Fax +47 22 82 75 01

Email:

Web:: www.wr.no

Bergen, Kobe, London, Oslo, Shanghai, Singapore

Show all Press releases

Wikborg Rein top rated in PLC

March 2011

Wikborg Rein are highly rated in several key industry areas.

As the only Norwegian law firm we are rated leading in Asset Finance (Shipping). We are also rated leading in Insurance and Banking Finance. Wikborg Rein are highly recommended in several other practice areas, including Competition/anti-trust and Investment funds.

For more information please visit www.wr.no
Wikborg Rein

Search News and Articles

Legal Developments by:
Wikborg Rein

Changes to the Norwegian prospectus rules

On 11 May 2012 certain changes to the Norwegian prospectus rules were proposed to the Norwegian parliament to ensure compliance with Directive 2010/73 EU.

- Wikborg Rein

Legal Developments in Norway

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Norway not included when short sale regulations in EU take effect 1 November 2012

From 1 November 2012 EU Regulation 236/2012 on short selling and certain aspects of credit default swaps will come into effect. Although the Regulation is within the scope of the EEA Agreement, Norway has not implemented the EU Regulation. Based on unofficial information from the Norwegian authorities, we expect the implementation process to be delayed until at least late 2013. Meanwhile, existing rules on short sale in Norway will continue to apply for transactions performed on the Norwegian market.

- Kluge Advokatfirma DA
Proposed ban on personal import of medicinal products ordered via Internet

The Ministry of Health and Care has recently issued a hearing letter proposing stringent restrictions on import of medicinal products for personal use. Among the actions proposed, is a general ban on the import of prescription drugs, and access for Customs to seize and destroy falsified or illegal medicinal products.

- Advokatfirmaet Grette DA
Increased transparency for applications for marketing authorisation

On 17th July 2012, the Norwegian Medicines Agency (NMA) announced a change in their practice regarding disclosure of information for applications of marketing authorisations for medicinal products.

- Advokatfirmaet Grette DA
New Patent Office Act to enter into effect on 1st January 2013

A new Act on the Patent Office and Industrial Property Rights Appeals Commission (the Patent Office Act) will be enacted and come into effect on 1st January 2013. The current Act on the Industrial Property Protection Board was enacted in 1910, and time for a complete reform had come.

- Advokatfirmaet Grette DA
Sunset clause for medicinal products in Norway

"Sunset clause" is a common term for the provision which could lead to the cessation of the validity of the marketing authorisation of a medicinal product.

- Advokatfirmaet Grette DA
New review on pension schemes

Questions on pensions have long had a large political focus in Norway, in connection with pension reforms such as obligatory occupational pension and changes in the National Insurance Scheme.

- Advokatfirmaet Grette DA
New provisions on competition clauses

In 2011 it was expected that new provisions for competition clauses, customer clauses and non-recruitment clauses would come into force. As early as June 2010, the Department of Employment sent a proposal on new provisions in the Working Environment Act for comments.

- Advokatfirmaet Grette DA
Norway implements the EU block exemption regulation for R&D agreements

Earlier this year, EU Commission Regulation No 1217/2010 was implemented in Norwegian law.

- Advokatfirmaet Grette DA
Hearing: Reimbursement of off-label use of medicinal products

In accordance with the provisions of the Act on Medicines and the appurtenant Regulation on Medicinal Products, pre-approved reimbursement for use of a medicinal product outside the approved indications of the marketing authorization is not allowed.

- Advokatfirmaet Grette DA
New review on pension schemes

Questions on pensions have long had a large political focus in Norway, in connection with pension reforms such as obligatory occupational pension and changes in the National Insurance Scheme.

- Advokatfirmaet Grette DA